SSA
KRRO icon

Schonfeld Strategic Advisors’s Korro Bio KRRO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$950K – 2129
2021
Q1 		$950K Buy
+2,000
New +$3.89M 0.01% 912

Other funds holding KRRO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Schonfeld Strategic Advisors's KRRO Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Korro Bio (KRRO) in Q4 2025, closing a stake of 90,186 shares — an estimated $4.32M sold.

Schonfeld Strategic Advisors first reported a position in KRRO in Q1 2021 and held it in 7 quarters. The position peaked at $4.77M in Q3 2024. 83 funds tracked by Wall St. Rank hold KRRO as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Korro Bio position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 90,186 Korro Bio shares in Q4 2025, an estimated $4.32M.
  • Schonfeld Strategic Advisors first reported a position in Korro Bio in Q1 2021 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Korro Bio position peaked at $4.77M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held Korro Bio as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.